Eight flavonoids and their potential as inhibitors of human cytomegalovirus replication

Antiviral Research

Volumn 96, Issue 2, 2012, Pages 181-186

  Cotin, Sébastien ^a   Calliste, Claude Alain ^b   Mazeron, Marie Christine ^d   Hantz, Sébastien ^a,c   Duroux, Jean Luc ^b   Rawlinson, William D ^a,c,e,f   Ploy, Marie Cécile ^a   Alain, Sophie ^a,c  

^a UMR 1092   (France)

^b UNIVERSITY OF LIMOGES   (France)

^c LIMOGES UNIVERSITY HOSPITAL   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e PRINCE OF WALES HOSPITAL   (Australia)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Antiviral; Cytomegalovirus; Flavonoids; Toxicity

Indexed keywords

2',3',4' TRIHYDROXYCHALCONE; 2,2',4' TRIHYDROXYCHALCONE; BAICALEIN; BUTEIN; FLAVONOID; GALLIC ACID; NARINGENIN; NARINGENIN CHALCONE; QUERCETAGETIN; QUERCETIN; UNCLASSIFIED DRUG;

ARTICLE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; PRIORITY JOURNAL; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CELL LINE; CYTOMEGALOVIRUS; FLAVONOIDS; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; VIRAL PLAQUE ASSAY; VIRUS REPLICATION;

CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 5;

EID: 84867237189     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2012.09.010     Document Type: Article

References (20)

1. Amoros M., Simoes C.M., Girre L., Sauvager F., Cormier M. Synergistic effect of flavones and flavonols against herpes simplex virus type 1 in cell culture. Comparison with the antiviral activity of propolis. J. Nat. Prod. 1992, 55:1732-1740.
2. Baldanti F., Lurain N., Gerna G. Clinical and biologic aspects of human cytomegalovirus resistance to antiviral drugs. Hum. Immunol. 2004, 65:403-409.
3. Balfour H.H. Antiviral drugs. N. Engl. J. Med. 1999, 340:1255-1268.
4. Beecher G.R. Overview of dietary flavonoids: nomenclature, occurrence and intake. J. Nutr. 2003, 133:3248S-3254S.
5. Cazarolli L.H., Zanatta L., Alberton E.H., Figueiredo M.S., Folador P., Damazio R.G., Pizzolatti M.G., Silva F.R. Flavonoids: prospective drug candidates. Mini Rev. Med. Chem. 2008, 8:1429-1440.
6. Danve C., Morfin F., Thouvenot D., Aymard M. A screening dye-uptake assay to evaluate in vitro susceptibility of herpes simplex virus isolates to acyclovir. J. Virol. Methods 2002, 105:207-217.
7. Ducancelle A., Alain S., Petit F., Sanson Le Pors M.J., Mazeron M.C. Development and validation of a non-radioactive DNA polymerase assay for studying cytomegalovirus resistance to foscarnet. J. Virol. Methods 2007, 141:212-215.
8. Evers D.L., Chao C.F., Wang X., Zhang Z., Huong S.M., Huang E.S. Human cytomegalovirus-inhibitory flavonoids: studies on antiviral activity and mechanism of action. Antiviral Res. 2005, 68:124-134.
9. Goldstein L.C., McDougall J., Hackman R., Meyers J.D., Thomas E.D., Nowinski R.C. Monoclonal antibodies to cytomegalovirus: rapid identification of clinical isolates and preliminary use in diagnosis of cytomegalovirus pneumonia. Infect. Immun. 1982, 38:273-281.
10. Hantz S., Garnier-Geoffroy F., Mazeron M.C., Garrigue I., Merville P., Mengelle C., Rostaing L., Saint Marcoux F., Essig M., Rerolle J.P., Cotin S., Germi R., Pillet S., Lebranchu Y., Turlure P., Alain S. Drug-resistant cytomegalovirus in transplant recipients: a French cohort study. J. Antimicrob. Chemother. 2010, 65:2628-2640.
11. Haun L., Kwan N., Hollier L.M. Viral infections in pregnancy. Minerva Ginecol. 2007, 59:159-174.
12. Hayashi K., Hayashi T., Otsuka H., Takeda Y. Antiviral activity of 5,6,7-trimethoxyflavone and its potentiation of the antiherpes activity of acyclovir. J. Antimicrob. Chemother. 1997, 39:821-824.
13. Hippenmeyer P.J., Dilworth V.M. A rapid assay for determination of antiviral activity against human cytomegalovirus. Antiviral Res. 1996, 32:35-42.
14. Lin Y.M., Flavin M.T., Schure R., Chen F.C., Sidwell R., Barnard D.L., Huffman J.H., Kern E.R. Antiviral activities of biflavonoids. Planta Med. 1999, 65:120-125.
15. Lyu S.Y., Rhim J.Y., Park W.B. Antiherpetic activities of flavonoids against herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) in vitro. Arch. Pharm. Res. 2005, 28:1293-1301.
16. Mitrocotsa D., Mitaku S., Axarlis S., Harvala C., Malamas M. Evaluation of the antiviral activity of kaempferol and its glycosides against human cytomegalovirus. Planta Med. 2000, 66:377-379.
17. Mocarski E.S., Shenk T., Pass R.F. Cytomegaloviruses. Fields Virology 2007, 2701-2772. Lippincott Williams & Wilkins, Philadelphia. D.M. Knipe, P.M. Howley (Eds.).
18. Nassetta L., Kimberlin D., Whitley R. Treatment of congenital cytomegalovirus infection: implications for future therapeutic strategies. J. Antimicrob. Chemother. 2009, 63:862-867.
19. Spaete R.R., Mocarski E.S. Insertion and deletion mutagenesis of the human cytomegalovirus genome. Proc. Natl. Acad. Sci. USA 1987, 84:7213-7217.
20. Weislow O.S., Kiser R., Fine D.L., Bader J., Shoemaker R.H., Boyd M.R. New soluble-formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity. J. Natl. Cancer Inst. 1989, 81:577-586.